$TARA

Shefferman Jesse sold $882K of TARA

Shefferman Jesse (CEO and President) sold 215,687 shares of Protara Therapeutics, Inc. (TARA) at $4.09 ($0.88M total) on 2026-06-29.

Original reporting
SEC EDGAR · Shefferman Jesse
Published Jul 1, 2026, 8:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TARA
Neutral
medium confidence
Mentioned
$TARA
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TARANeutralLow
01

Why it matters

This is a new, concrete datapoint on CEO share disposal (215,687 shares at $4.09) but lacks any accompanying company-specific fundamental update.

02

Market read

Insider selling can modestly influence sentiment, but without additional catalysts it is unlikely to drive a sustained repricing.

03

What to watch

Traders may want to compare this sale to prior insider activity (frequency/size) and whether other insiders filed concurrent transactions, which are not provided here.

Relevance 5/10Novelty 5/10Timing: after-hours/filing timestamp July 1, 2026 (Form 4)

Background

The article is an SEC Form 4 insider transaction disclosure for Protara Therapeutics, Inc. (TARA).

Company-level read

Ticker impact

$TARANeutralMedium confidence
Context

Protara Therapeutics CEO Jesse Shefferman sold 215,687 shares in an open-market transaction for about $882K, per Form 4 filed July 1.

Expected impact

Low near-term impact; any effect is likely sentiment-driven and limited unless follow-on selling accelerates.

Evidence & confidence

The filing is a primary-source Form 4 with transaction size and price, but it does not include new guidance, trial results, or material corporate events.

Market effects

Minimal; insider-sale disclosures typically do not change sector fundamentals without accompanying company-specific news.

None indicated.

None indicated.

Counterpoint

The sale could be driven by diversification or pre-planned liquidity needs rather than negative fundamentals, especially since it references no 10b5-1 plan.

Key entities

  • Protara Therapeutics, Inc.

    Subject of the Form 4 insider transaction; CEO and President Jesse Shefferman sold shares.

  • Jesse Shefferman

    CEO and President who executed the open-market sale disclosed in the Form 4.

Related articles